spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Rapamycin 

 HSMN NewsFeed - 4 Apr 2022
FDA approves Nobelpharma's HYFTOR(TM) (sirolimus topical gel) 0.2%
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Feb 2020
Vividion Therapeutics Appoints Drug Discovery and Development Expert, Robert Abraham, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2015
Navitor Pharmaceuticals Announces $33 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Nov 2013
Svelte Medical Systems Announces Enrollment Complete in the DIRECT II Drug-Eluting Stent Study
Devices Interventional Cardiology
 HSMN NewsFeed - 23 May 2013
Svelte Drug-Eluting Stent Utilizing New Class of Bioabsorbable Drug Coating Attains 0% Clinically-Driven Events Through 12-Months in First-In-Man Study
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Jan 2013
Svelte Medical Systems Announces Treatment of First Patient in the DIRECT II Drug-Eluting Stent Study
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Aug 2012
Cardionovum(R) Expects to Launch Next-Generation Product: Drug-Eluting Coronary Stent System, “PROLIMUS Biograde”
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2012
Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2010
Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2010
Novartis Receives US FDA Approval for Zortress(R) (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Oct 2009
MacuSight(R) Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 23 Sep 2009
Elixir Medical Corporation Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorbable Polymers
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2009
AMG International Announces the European Regulatory Submission of its Next Generation of Coronary Drug Stents 'Itrix' at European PCR Congress in Barcelona, Spain
Device,s Interventional Cardiology
 HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Diagnostics Oncology
 HSMN NewsFeed - 6 Nov 2008
MacuSight Appoints Gerald Wroblewski Vice President of Operations
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 30 Oct 2008
SurModics Licenses Hydrophilic Coating for Elixir's Drug-Eluting and Bare Metal Stent Delivery Systems
Devices Interventional Cardiology Licensing
 HSMN NewsFeed - 16 Oct 2008
Elixir Medical Corporation Announced Positive First-In-Man Results from Three Drug Eluting Coronary Stent Systems
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2008
Elixir Medical Corporation Licenses Myolimus(TM) From Novartis Pharma AG for Site-Specific Drug Delivery Applications
Devices Drug Delivery Licensing Interventional Cardiology
 HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 20 Feb 2008
New Breakthrough Treatment for Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Feb 2008
MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 4 Feb 2008
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
Devices Licensing
 HSMN NewsFeed - 28 Jan 2008
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Aug 2007
Abraxis BioScience and The Scripps Research Institute Enter Exclusive Licensing Agreement for the Worldwide Development and Commercialization of a Novel Epothilone Therapeutic for the Treatment of Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Aug 2007
NCCN Updates Kidney Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2007
Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2007
Wyeth Provides Update on FDA Review of the Torisel New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Dec 2006
FDA Grants Torisel NDA Priority Review Status
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2006
MacuSight(TM) Appoints Brian C. Cunningham to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2006
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Biotica Enters into a Research and License Agreement with Wyeth for Novel Rapamycin Analogs
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Oct 2006
CV Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office and European Patent Office for Drug-Eluting Stent Technology
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
Rapamycin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.